Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
Links relacionados
- Similares en SciELO
Compartir
Revista argentina de dermatología
versión On-line ISSN 1851-300X
Resumen
MANFRIN, J. et al. Malignant Lentigo treated with imiquimod 5%. Presentation of a case and review of the subject. Rev. argent. dermatol. [online]. 2019, vol.100, n.3, pp.81-92. Epub 30-Sep-2019. ISSN 1851-300X.
Malignant lentigo (LM) is a variant of in situ melanoma that develops mainly in areas of chronic sun exposure in middle-aged patients. Without treatment, 5% to 50% of the LM can progress to a lentigo maligna melanoma (LMM).
Although the treatment of choice is surgical, imiquimod seems to be a viable and non-invasive option in patients with large tumors, elderly or people with underlying disease, or who simply reject the surgical removal of the lesion.
We present a case of LM satisfactorily treated with topical imiquimod.
Palabras clave : lentigo; malignant; melanoma; imiquimod; immunomodulator.